



Australian Government
Department of Health and Aged Care

NATIONAL IMMUNISATION PROGRAM BOARD

AGENDA

Wednesday, 20 June 2024

1:00pm – 2:00pm AEST

Webex & Level 1, Meeting room 1, Scarborough House

#	Item	Lead	Reviewer	Duration
s22				
4	National COVID-19 Vaccine Program – status update	Rachelle Davis	Elspeth Kay	20 Mins
s22				

Members	Division / Department	Proxy
Dr Anna Peatt, First Assistant Secretary	National Immunisation Division	
Dave McNally, Assistant Secretary	Immunisation Program Policy	
Rachelle Davis, Assistant Secretary	Supply and Distribution	
Genevieve Donnelly, Assistant Secretary	Provider Engagement, Communications & Compliance	
Kelly Fisher, Assistant Secretary	Immunisation reform	
Samira Hassan, Assistant Secretary	National Medical Stockpile, Health Security & Emergency Management Division	
Mark Roddam, First Assistant Secretary	Primary Care Division	
Trish Garrett, First Assistant Secretary	Service Delivery Division	
Avinash Clarke, Assistant Secretary	Health Protection & Workforce Branch	
Kayla Jordan, Assistant Secretary	Data and Analytics Branch	
Elsbeth Kay, Assistant Secretary	Pharmacovigilance Branch	
Leanne Ringwood, Assistant Secretary	Public Information Branch	
Lee Steel, First Assistant Secretary	Department of the Prime Minister and Cabinet	
Martin Rocks, Assistant Secretary	Department of Finance	
Invitee		
s 22	Department of the Prime Minister and Cabinet	
Observer		
s 22	Work Area	
s 22	Program Management Office, Primary Care and Community Group	
Secretariat		
s 22	Work Area	
s 22 Director	Program Management Office	
s 22 Secretariat	Program Management Office	
s 22 Secretariat	Program Management Office	

Dashboard

- There has been a nominal increase in vaccination coverage rates but the overall rate for older Australians is still a concern. A long-standing risk around vaccine uptake has been reframed to reflect this.
- Vaccines remain in a surplus of supply to approximately mid-2026.
- Forecast supply gaps of Novavax s22 vaccines are currently being managed with healthcare professionals. s22
- s22
- As advised in the action items from the last meeting, the 2023 Rapid Review of the 2023 booster program will inform considerations in terms of tailoring communications to the most at-risk population cohorts.

Assurance

- All assurance activities are on track, with the plan and schedule reflecting the current external assurance activity underway through April-May 2024.

Risks and Issues

- Risk workshops were recently undertaken to ensure the program risks are current with effective mitigation strategies. The paper provided to members details all risks for the Division, noting that not all of these risks relate solely to the NCVP.
- One of the action items from the last meeting was to consider whether the overall risk rating should be reviewed in terms of the impact of the NPP not being agreed.
 - This was considered and determined to be a dependency of the NCVP's critical program elements, but not a risk, as it does not affect the current scope of the Tier 1 project which has been approved to run until December 2024.
 - This dependency will be managed and used to inform contingency planning and mapping of sustainability requirements from January 2025 onwards. This dependency has been highlighted on the roadmap under 'program sustainability.'

s 22

National COVID-19 Vaccine Program (NCVP) Dashboard – May 2024

The program continues to trend green as it provides support to access to COVID-19 vaccines throughout 2024, whilst maintaining critical program elements in line with 2023-24 Government Initiatives. Based on latest reporting figures, 71.4 million COVID-19 vaccine doses have been administered since the program commenced.

s22

Supply - Novavax contract issues

- Vaccines remain in a surplus of supply, however will move to a sufficient supply environment in 2025.
- Forecasted supply gaps of Novavax s22 vaccines are currently being managed with Health Care Professionals, with supply of Novavax anticipated to resume in early 2025 s22
- Negotiations are underway with manufacturers to secure the most updated vaccines in the latest presentations i.e. JN.1 vaccines (On 26 April 2024, WHO recommend switch to JN.1 strain) and pre-filled syringes s22, subject to regulatory approvals.
- Early consultation with stakeholders on the Logistics Model Value Assessment is underway, including initial high-level discussions with State and Territory counterparts who have expressed interest in being involved. Requirements continue to be shaped with the procurement process to commence shortly to engage an external contractor to undertake the Value Assessment.

s22

s 22

ATAGI Vaccine Dashboard

s 22

s 22

TGA Stage

s 22

NUVAXOVID XBB.1.5 TBA
(Bioselect/Novavax)

s 22



Australian Government
Department of Health and Aged Care

NATIONAL IMMUNISATION PROGRAM BOARD

Regulatory status of COVID-19 vaccines and treatments

DATE OF MEETING: 20 June 2024

AGENDA ITEM: 5.1 D: Other Business

s 22

Regulatory status of COVID-19 vaccines

s 22

- On 21 May 2024 Bioclect Pty Ltd on behalf of Novavax Inc withdrew its application to fully register NUVAXOVID XBB.1.5 COVID-19 vaccine. This was a decision of the sponsor.

s 22

